Berberine ursodeoxycholate for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 4 Sep 2018: Trial registered, NCT03656744
  2. 26 Nov 2018: Trial started, NCT03656744
  3. 21 Nov 2022: Trial registered, NCT05623189
  4. 27 Dec 2022: Trial started, NCT05623189

The trials

NCT03656744: A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

State
Completed
Phase
Phase 2
People
101 taking part
Started
26 Nov 2018
Primary completion
7 Feb 2020
Arms
500mg HTD1801, bid, 1000mg HTD1801, bid
Results
Posted on the registry
  1. 4 Sep 2018: Trial registered
  2. 26 Nov 2018: Trial started
  3. 9 Mar 2020: Trial completed
  4. 29 Dec 2021: Trial results posted

NCT05623189: HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

State
Completed
Phase
Phase 2
People
218 taking part
Started
27 Dec 2022
Primary completion
31 Mar 2025
Arms
HTD1801
Results
None posted
  1. 21 Nov 2022: Trial registered
  2. 27 Dec 2022: Trial started
  3. 31 Mar 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.